« Back Urologic Oncology: Seminars and Original Investigations

Article in Press

Serum tumor markers in testicular cancer

  • Yaron Ehrlich, M.D.

      Affiliations

    • Department of Urology, School of Medicine, Melvin and Bren Simon Cancer Center, Indianapolis, IN 46292, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-317-274-3458; fax: +1-1-317-274-0174.
    • ,
  • Stephen D.W. Beck, M.D.

      Affiliations

    • Department of Urology, School of Medicine, Melvin and Bren Simon Cancer Center, Indianapolis, IN 46292, USA
    • ,
  • Richard S. Foster, M.D.

      Affiliations

    • Department of Urology, School of Medicine, Melvin and Bren Simon Cancer Center, Indianapolis, IN 46292, USA
    • ,
  • Richard Bihrle, M.D.

      Affiliations

    • Department of Urology, School of Medicine, Melvin and Bren Simon Cancer Center, Indianapolis, IN 46292, USA
    • ,
  • Lawrence H. Einhorn, M.D.

      Affiliations

    • Division of Hematology-Oncology, School of Medicine, Melvin and Bren Simon Cancer Center, Indianapolis, IN 46292, USA
    • Lance Armstrong Foundation Professor of Medicine.

Received 11 March 2010 ,Revised 23 April 2010 ,Accepted 26 April 2010. Published online 07 September 2010 Corrected Proof

References 

  1. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification (A prognostic factor-based staging system for metastatic germ cell cancers). J Clin Oncol. 1997;15:594–603
  2. In:  Fleming ID,  Cooper JS,  Henson DE, et al. editor. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven; 1997;p 225
  3. Gitlin D, Boesman M. Serum α-fetoprotein, albumin, and γ-G-globulin in the human conceptus. J Clin Invest. 1966;45:1826–1838
  4. Jacobsen GK. α-Fetoprotein (AFP) and human chorionic gonadotropin (HCG) in testicular germ cell tumours (A comparison of histologic and serologic occurrence of tumour markers). Acta Pathol Microbiol Immunol Scand A. 1983;91:183–190
  5. Talerman A, Haije WG, Baggerman L. Serum α-fetoprotein (AFP) in patients with germ cell tumors of the gonads and extragonadal sites: Correlation between endodermal sinus (yolk sac) tumor and raised serum AFP. Cancer. 1980;46:380–385
  6. Bell H. α-Fetoprotein and carcinoembryonic antigen in patients with primary liver carcinoma, metastatic liver disease, and alcoholic liver disease. Scand J Gastroenterol. 1982;17:897–903
  7. Waldmann TA, McIntire KR. The use of a radioimmunoassay for α-fetoprotein in the diagnosis of malignancy. Cancer. 1974;34;:suppl:1510–5
  8. Masopust J, Kithier K, Rádl J, et al. Occurrence of fetoprotein in patients with neoplasms and non-neoplastic diseases. Int J Cancer. 1968;3:364–373
  9. Kitau MJ, Grint PC, Heath RB, et al. Serum α-fetoprotein levels in subjects infected with hepatitis B virus. J Med Virol. 1988;26:437–442
  10. Schefer H, Mattmann S, Joss RA. Hereditary persistence of α-fetoprotein (Case report and review of the literature). Ann Oncol. 1998;9:667–672
  11. Johnson PJ, Poon TC, Hjelm NM, et al. Glycan composition of serum α-fetoprotein in patients with hepatocellular carcinoma and nonseminomatous germ cell tumour. Br J Cancer. 1999;81:1188–1195
  12. Mora J, Gascon N, Tabernero JM, et al. α-Fetoprotein-concanavalin A binding as a marker to discriminate between germ cell tumours and liver diseases. Eur J Cancer. 1995;3:2239–2242
  13. Kawai K, Kojima T, Miyanaga N, et al. Lectin-reactive α-fetoprotein as a marker for testicular tumor activity. Int J Urol. 2005;12:284–289
  14. Mora J, Garrido A, Antonijuan A, et al. Applicability of α-fetoprotein-concanavalin A (AFP-ConA) binding to discriminate between germinal or hepatic origin of AFP in germ cell tumour patients during chemotherapy or follow-up. Clin Chem Lab Med. 2007;45:932–933
  15. de Takats PG, Jones SR, Penn R, et al. α-Fetoprotein heterogeneity: What is its value in managing patients with germ cell tumours?. Clin Oncol (R Coll Radiol). 1996;8:323–326
  16. von Eyben FE. Laboratory markers and germ cell tumors. Crit Rev Clin Lab Sci. 2003;40:377–427
  17. Vaitukaitis JL, Braunstein GD, Ross GT. A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Am J Obstet Gynecol. 1972;113:751–758
  18. Odell WD, Griffin J. Pulsatile secretion of human chorionic gonadotropin in normal adults. N Engl J Med. 1987;317:1688–1691
  19. Stenman UH, Alfthan H, Ranta T, et al. Serum levels of human chorionic gonadotropin in nonpregnant women and men are modulated by gonadotropin-releasing hormone and sex steroids. J Clin Endocrinol Metab. 1987;64:730–736
  20. Catalona WJ, Vaitukaitis JL, Fair WR. Falsely positive specific human chorionic gonadotropin assays in patients with testicular tumors: Conversion to negative with testosterone administration. J Urol. 1979;122:126–128
  21. Garnick MB. Spurious rise in human chorionic gonadotropin induced by marihuana in patients with testicular cancer. N Engl J Med. 1980;303:1177
  22. Braunstein GD, Thompson R, Gross S, et al. Marijuana use does not spuriously elevate serum human chorionic gonadotropin levels. Urology. 1985;25:605–606
  23. Markert CL. Lactate dehydrogenase isozymes: Dissociation and recombination of subunits. Science. 1963;140:1329–1330
  24. Ackers C, Rustin GJ. Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage 1 germ cell tumours. Br J Cancer. 2006;94:1231–1232
  25. Venkitaraman R, Johnson B, Huddart RA, et al. The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours. BJU Int. 2007;100:30–32
  26. Weissbach L, Bussar-Maatz R, Mann K. The value of tumor markers in testicular seminomas (Results of a prospective multicenter study). Eur Urol. 1997;32:16–22
  27. Huddart RA, O'Doherty MJ, Padhani A, et al. 18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage 1 nonseminomatous germ cell tumors: Preliminary report of MRC Trial TE22—the NCRI Testis Tumour Clinical Study Group. J Clin Oncol. 2007;25:3090–3095
  28. Beck SD, Foster RS, Bihrle R, et al. Significance of primary tumor size and pre-orchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical stage A nonseminomatous germ cell tumors. Urology. 2007;69:557–559
  29. Colls BM, Harvey VJ, Skelton L, et al. Late results of surveillance of clinical stage 1 nonseminoma germ cell testicular tumours: 17 Years' experience in a national study in New Zealand. BJU Int. 1999;83:76–82
  30. Germà-Lluch JR, Garcia del Muro X, Maroto P, et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: The experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol. 2002;42:553–562
  31. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage 1 testicular teratoma (Medical Research Council Testicular Tumors Working Party). J Clin Oncol. 1992;10:1762–1768
  32. Klepp O, Olsson AM, Henrikson H, et al. Prognostic factors in clinically stage 1 nonseminomatous germ cell tumors of the testis (Multivariate analysis of a prospective multicenter study Swedish-Norwegian Testicular Cancer Group). J Clin Oncol. 1990;8:509–518
  33. Divrik RT, Akdogan B, Ozen H, et al. Outcomes of surveillance protocol of clinical stage 1 nonseminomatous germ cell tumors-is shift to risk adapted policy justified?. J Urol. 2006;176:1424–1429
  34. Kollmannsberger C, Moore C, Chi KN, et al. Non-risk-adapted surveillance for patients with stage 1 nonseminomatous testicular germ-cell tumors: Diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 2010;21:1296–301.
  35. Sturgeon JF, Jewett MA, Alison RE, et al. Surveillance after orchidectomy for patients with clinical stage 1 nonseminomatous testis tumors. J Clin Oncol. 1992;10:564–568
  36. Klepp O, Dahl O, Flodgren P, et al. Risk-adapted treatment of clinical stage 1 nonseminoma testis cancer. Eur J Cancer. 1997;33:1038–1044
  37. Trigo JM, Tabernero JM, Paz-Ares L, et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer. 2000;88:162–168
  38. Saxman SB, Nichols CR, Foster RS, et al. The management of patients with clinical stage 1 nonseminomatous testicular tumors and persistently elevated serologic markers. J Urol. 1996;155:587–589
  39. Dash A, Carver BS, Stasi J, et al. The indication for post-chemotherapy lymph node dissection in clinical stage 1s nonseminomatous germ cell tumor. Cancer. 2008;112:800–805
  40. Bosl GJ, Geller NL, Cirrincione C, et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res. 1983;43:3403–3407
  41. Fossa SD, Oliver RT, Stenning SP, et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer. 1997;33:1380–1387
  42. von Eyben FE, Madsen EL, Fritsche H, et al. A new prognostic model for testicular germ cell tumours. APMIS. 2003;111:100–105
  43. Weissbach L, Bussar-Maatz R, Lohrs U, et al. Prognostic factors in seminomas with special respect to HCG: Results of a prospective multicenter study (Seminoma Study Group). Eur Urol. 1999;36:601–608
  44. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol. 1989;7:387–391
  45. Ehrlich Y, Brames JM, Beck SDW, et al. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: Is a post-chemotherapy retroperitoneal lymph node dissection needed following complete remission?. J Clin Oncol. 2010;28:531–536
  46. de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15:1837–1843
  47. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19:1629–1640
  48. Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups. J Clin Oncol. 1995;13:1177–1187
  49. Coogan CL, Foster RS, Rowland RG, et al. Post-chemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology. 1997;50:957–962
  50. Oldenburg J, Alfsen GC, Lien HH, et al. Post-chemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 2003;21:3310–3317
  51. Morris MJ, Bosl GJ. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol. 2000;163:796–801
  52. Zon RT, Nichols C, Einhorn LH. Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol. 1998;16:1294–1297
  53. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol. 1998;16:1287–1293
  54. Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol. 1996;14:2638–2645
  55. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340–348
  56. Toner GC. Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: Still not ready for routine clinical use. J Clin Oncol. 2004;22:3842–3845
  57. Vogelzang NJ, Lange PH, Goldman A, et al. Acute changes of α-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res. 1982;42:4855–4861
  58. Fizazi K, Culine S, Kramar A, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol. 2004;22:3868–3876
  59. Gerl A, Clemm C, Lamerz R, et al. Prognostic implications of tumour marker analysis in nonseminomatous germ cell tumours with poor prognosis metastatic disease. Eur J Cancer. 1993;29A:961–965
  60. Stevens MJ, Norman AR, Dearnaley DP, et al. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol. 1995;13:87–92
  61. Motzer RJ, Mazumdar M, Gulati SC, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst. 1993;85:1828–1835
  62. Motzer RJ, Mazumdar M, Bajorin DF, et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol. 1997;15:2546–2552
  63. Olofsson S, Dahl O, Jerkeman M, et al. Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA. J Clin Oncol. 2009;27:15s
  64. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247–256
  65. Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin Oncol. 1995;13:1170–1176
  66. Dieckmann KP, Albers P, Classen J, et al. Late relapse of testicular germ cell neoplasms: A descriptive analysis of 122 cases. J Urol. 2005;173:824–829
  67. George DW, Foster RS, Hromas RA, et al. Update on late relapse of germ cell tumor: A clinical and molecular analysis. J Clin Oncol. 2003;21:113–122
  68. Gerl A, Clemm C, Schmeller N, et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol. 1997;8:41–47
  69. Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol. 2005;23:6999–7004
  70. Lipphardt ME, Albers P. Late relapse of testicular cancer. World J Urol. 2004;22:47–54
  71. Ehrlich Y, Baniel J. Late relapse of testis cancer. Urol Clin North Am. 2007;34:253–258
  72. Albers P, Ganz A, Hannig E, et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol. 2000;164:381–384
  73. Wood DP, Herr HW, Motzer RJ, et al. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer. 1992;70:2354–2357
  74. Eastham JA, Wilson TG, Russell C, et al. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology. 1994;43:74–80
  75. Ravi R, Ong J, Oliver RT, et al. Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. Br J Urol. 1998;81:884–888
  76. Beck SD, Foster RS, Bihrle R, et al. Outcome analysis for patients with elevated serum tumor markers at post-chemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2005;23:6149–6156
  77. van Dijk MR, Steyerberg EW, Habbema JD. Survival of nonseminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer. 2006;42:820–826

PII: S1078-1439(10)00117-1

doi: 10.1016/j.urolonc.2010.04.007

« Back Urologic Oncology: Seminars and Original Investigations

Article in Press

Article Tools